Outlook Therapeutics

Q3 FY2026 EarningsFY26 Q3 delivered a significant revenue beat of $1.4M (actual) vs. $0.97M (expected), driven by the ongoing European launch of LYTENAVA in Germany, the UK, and Austria. However, the company continues to face severe operational headwinds, with a GAAP Net Loss of -$62.4M and a substantial doubt regarding its ability to continue as a going concern, as existing cash is only sufficient to fund operations through September 2026. While the recent FDA approval of LYTENAVA in the US (July 2026) provides a major catalyst, the heavy reliance on a single product and the urgent need for substantial capital represent critical risks.